Sioud Mouldy
Department of Immunology, Institute for Cancer Research, Oslo University Hospital, Montebello, Oslo, N-310, Norway,
Methods Mol Biol. 2015;1218:301-19. doi: 10.1007/978-1-4939-1538-5_19.
RNA interference (RNAi) is a conserved regulatory mechanism of posttranscriptional gene silencing triggered by either endogenously (e.g. microRNAs) or exogenously double-stranded RNA as small interfering (si) RNAs. To date, the use of siRNA (21-nt) has become a standard laboratory tool to silence gene expression in mammalian cells in-vitro and in-vivo. The methodology also holds promise for treating a diversity of human diseases. However, one of the challenges of making siRNAs as therapeutic drugs includes the activation of innate immunity and silencing of unwanted genes. Therefore, the use of siRNAs in functional genomics and human therapies depends on the development of strategies to overcome siRNA unwanted effects. This chapter highlights some efficient strategies aimed at separating gene silencing from immunostimulation and improving siRNA gene silencing specificity.
RNA干扰(RNAi)是一种保守的转录后基因沉默调控机制,由内源性(如微小RNA)或外源性双链RNA作为小干扰(si)RNA触发。迄今为止,使用siRNA(21个核苷酸)已成为在体外和体内沉默哺乳动物细胞中基因表达的标准实验室工具。该方法在治疗多种人类疾病方面也具有前景。然而,将siRNA制成治疗药物的挑战之一包括激活先天免疫和沉默不需要的基因。因此,siRNA在功能基因组学和人类治疗中的应用取决于克服siRNA不良影响的策略的发展。本章重点介绍了一些旨在将基因沉默与免疫刺激分离并提高siRNA基因沉默特异性的有效策略。